Briacell Therap (NASDAQ:BCTX) Releases Quarterly Earnings Results

Briacell Therap (NASDAQ:BCTX) posted its quarterly earnings data on Tuesday. The company reported ($0.99) earnings per share (EPS) for the quarter, Zacks reports.

Briacell Therap Price Performance

Shares of NASDAQ BCTX opened at $3.07 on Wednesday. The stock’s 50-day moving average is $3.90 and its two-hundred day moving average is $5.42. Briacell Therap has a 1-year low of $2.93 and a 1-year high of $36.00. The company has a market cap of $26.71 million, a price-to-earnings ratio of -0.13 and a beta of 1.21.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on BCTX shares. Wall Street Zen upgraded Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.